# Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals

> **NCT01836068** · EARLY_PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 11 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Enfuvirtide

## Key facts

- **NCT ID:** NCT01836068
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2020-01-22
- **Final completion:** 2021-06-05
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2021-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01836068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01836068, "Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01836068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*